Leading the Fight Against Pet Cancer

Bridging the Gap in Canine Oncology

Each year, over 6 million dogs are diagnosed with cancer, a figure that notably exceeds the 1.9 million human cancer incidence rate. In the U.S., there are merely nine approved cancer treatments for veterinary use, many of which rely on outdated technologies. This scarcity is compounded by limited insurance coverage, hindering access to crucial care for numerous pets and their families.

Jenga's Vision: A New Era of Cancer Care

Jenga is on a mission to arm veterinarians with cutting-edge, effective cancer treatments. We strive to broaden the accessibility of advanced cancer care for pets in need, aiming to transform the landscape of veterinary oncology.

Crafting a Future Where Every Pet Thrives

Committed to overcoming existing barriers in cancer treatment, Jenga is forging a path toward a future where all pets can enjoy healthier, fuller lives. By expanding therapeutic innovations, we seek to improve health outcomes for pets, providing their families with reassurance and hope. Through relentless innovation and unwavering dedication, Jenga is set to elevate veterinary care, guaranteeing the best possible treatments are within reach for pets everywhere.

Leadership Team

  • Julia Stephanus

    Executive Chair and Borealis Partner

  • Kevin Isett, PhD

    Borealis Advisor

  • David Brake, PhD

    Bioquest, Regulatory

Scientific Advisory Board

  • Timothy Fan DVM, PhD, DACVIM (SAIM), DACVIM (Oncology)

    University of Illinois Cancer Center

  • Ira Gordon, DVM DACVR-RO

    VANE Co-Founder

  • Howard Kaufman MD Ph.D.

    Ankyra Therapeutics CEO

  • Heather Wilson-Robles DVM, DACVIM

    The Oncology Service, Springfield, VA